Apr. 19 at 1:11 PM
$CTMX As of January 2026, a total of 26 patients who received CX2501 at a dose of 10 mg/kg were eligible for efficacy evaluation. Among them, 9 achieved a confirmed partial response, corresponding to an objective response rate (ORR) of approximately 35%, and around 90% demonstrated stable disease. The efficacy of CX2501 is comparable to that of approved ADC drugs. Regarding its safety profile, no cases of ILD, febrile neutropenia or pancreatitis were observed. The most common adverse event was diarrhea, which was predictable and manageable. The drug has the potential to become a first in class drug to target Epcam expressed cancers.
